Kalliopi KERAMIDA
Balkan Medical Journal - 2026;43(4):171-173
The year 2025 marked an important step forward for cardio-oncology, with advances spanning mechanistic discovery, prevention-oriented trials, risk stratification, and expert consensus statements that collectively signal a transition toward precision cardiovascular (CV) care. This editorial presents a focused narrative selection of high-impact 2025 contributions-covering anthracycline (AC)/human epidermal growth factor receptor 2 (HER2) therapies related cardiotoxicity, immune checkpoint inhibitors (ICIs), prevention strategies, survivorship, and key statements-rather than a systematic review.
